Profil
Kjell Rensfeldt worked as a Principal at Biogen, Inc. and Q-Med AB.
He also worked at Moberg Pharma AB from 2007 to 2018, where he held the position of Chief Medical Officer & VP-Clinical Development from 2012 to 2013.
Anciens postes connus de Kjell Rensfeldt
| Sociétés | Poste | Fin |
|---|---|---|
| MOBERG PHARMA AB | Directeur Technique/Scientifique/R&D | 13/08/2018 |
Q-Med AB
 Q-Med AB Medical SpecialtiesHealth Technology Q-Med AB specializes in aesthetic and corrective solutions. It develops and manufactures brand management for aesthetic and corrective treatments, whereas its portfolio is based on the company’s patented technology, NASHA, for the production of stabilise of non-animal hyaluronic acid. The firm offers portfolio including the brands Restylane, Emervel, Azzalure, Dysport, Deflux, Solesta, and Durolane are other products improving patients’ health in the corrective field. The company was founded by Bengt Agerup on June 17, 1985 and is headquartered in Uppsala, Sweden. | Corporate Officer/Principal | - |
| BIOGEN INC. | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MOBERG PHARMA AB | Health Technology |
| BIOGEN INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Q-Med AB
Q-Med AB Medical SpecialtiesHealth Technology Q-Med AB specializes in aesthetic and corrective solutions. It develops and manufactures brand management for aesthetic and corrective treatments, whereas its portfolio is based on the company’s patented technology, NASHA, for the production of stabilise of non-animal hyaluronic acid. The firm offers portfolio including the brands Restylane, Emervel, Azzalure, Dysport, Deflux, Solesta, and Durolane are other products improving patients’ health in the corrective field. The company was founded by Bengt Agerup on June 17, 1985 and is headquartered in Uppsala, Sweden. | Health Technology |